Business Description
Inhibitor Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US42278K1025
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.58 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -81.7 | |||||
3-Year EPS without NRI Growth Rate | -88.2 | |||||
3-Year FCF Growth Rate | -100 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 66.8 | |||||
9-Day RSI | 60.98 | |||||
14-Day RSI | 58.04 | |||||
6-1 Month Momentum % | 1 | |||||
12-1 Month Momentum % | 43.71 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 199.25 | |||||
Quick Ratio | 199.25 | |||||
Cash Ratio | 197.19 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 22.8 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -54.64 | |||||
ROA % | -34.56 | |||||
ROIC % | -13050 | |||||
ROC (Joel Greenblatt) % | -12276.92 | |||||
ROCE % | -37.44 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 4.24 | |||||
Price-to-Tangible-Book | 4.24 | |||||
EV-to-EBIT | -1.24 | |||||
EV-to-EBITDA | -1.24 | |||||
EV-to-FCF | -1.32 | |||||
Price-to-Projected-FCF | 2.83 | |||||
Price-to-Net-Current-Asset-Value | 4.24 | |||||
Price-to-Net-Cash | 4.24 | |||||
Earnings Yield (Greenblatt) % | -80.65 | |||||
FCF Yield % | -20.54 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:INTI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Inhibitor Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -0.021 | ||
Beta | -0.59 | ||
Volatility % | 89.07 | ||
14-Day RSI | 58.04 | ||
14-Day ATR ($) | 0.006585 | ||
20-Day SMA ($) | 0.082003 | ||
12-1 Month Momentum % | 43.71 | ||
52-Week Range ($) | 0.03355 - 0.2999 | ||
Shares Outstanding (Mil) | 172.32 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Inhibitor Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Inhibitor Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Inhibitor Therapeutics Inc Frequently Asked Questions
What is Inhibitor Therapeutics Inc(INTI)'s stock price today?
When is next earnings date of Inhibitor Therapeutics Inc(INTI)?
Does Inhibitor Therapeutics Inc(INTI) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |